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creativecommons.org/tioning among elders with and without Alzheimer’s disease (AD) and determine the predictive ability
of combined molecular markers and select neuropsychological tests in detecting disease presence.
Methods: Data were analyzed from 300 participants (n5 150, AD and n5 150, controls) enrolled in
the Texas Alzheimer’s Research and Care Consortium. Linear regression models were created to
examine the link between the top five molecular markers from our AD blood profile and neuropsy-
chological test scores. Logistical regressions were used to predict AD presence using serum
biomarkers in combination with select neuropsychological measures.
Results: Using the neuropsychological test with the least amount of variance overlap with the
molecular markers, the combined neuropsychological test and molecular markers was highly
accurate in detecting AD presence.
Conclusion: This work provides the foundation for the generation of a point-of-care device that can
be used to screen for AD.
 2015 Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords: Alzheimer’s disease; Diagnosis; Biomarkers; Verbal fluency1. Introduction
Alzheimer’s disease (AD) is themost prevalent form of de-
mentia and is estimated to cost the U.S. healthcare system
nearly $1.1 trillion dollars by the year 2050 [1]. Because of
the growing prevalence rate of AD and the increase in preven-
tative healthcare measures, which enable individuals to live
longer, it is believed that over 80% of those 65 years and
more will experience cognitive decline associated with AD
[1]. Thus the importance of identifying early AD symptoms
has increased as the burden on the healthcare systemcontinues
to grow. Recent work has sought to establish a rapid and cost-
effective means of identifying those with early AD, through
creating a blood test to screen for disease presence [2–6].thor. Tel.: 817-735-2961; Fax: 817-735-0628.
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licenses/by-nc-nd/4.0/).Through this work, researchers have sought to provide util-
ity for identifying blood-based biomarkers associated with
neuropsychological functioning to establish biomarker pro-
files of disease states [7]. This effort termedMolecular Neuro-
psychology has identified biomarker profiles of
neurocognitive functioning and begun combining select blood
biomarkers with select cognitive assessments with the goal of
establishing a point-of-care device for primary care settings
that can be used to identify those with early AD [7,8]. This
work has stemmed from the growing need for a rapid
screening measure for those early in the disease process.
Thesemethods can also be used for screening in clinical trials.
Initial work by Ray and colleagues established an 18-
plasma-based blood test to differentiate those with AD
from those with normal cognition, with an overall accuracy
of 89% [9]. This work was built on by O’Bryant and col-
leagues [2–4] who examined the implications of usingation. This is an open access article under the CC BY-NC-ND license (http://
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presence. In our most recent work, we generated a blood test
based profile consisting of 21 serum proteins, which yielded
an accuracy of 96% in identifying those with AD from those
with normal cognition [4]. The top five serum proteins
included in the blood-test were interleukin 5 (IL-5), IL-6,
IL-7, tumor necrosis factor-alpha (TNF-a), and C-reactive
protein (CRP) [4].
In our recent work, we demonstrated that combining two
of the top five biomarkers (TNF-a and IL-7) with one neuro-
psychological measure (Clock 4-point), yielded excellent
accuracy in detecting early AD [8]. Even for very early
AD cases, this approach was able to provide an overall accu-
racy of 91% with a sensitivity of 97% and specificity of 72%
[8]. This work has shown that combining neuropsychologi-
cal screening measures with a limited number of biomarkers
can increase the ability to identify those who are at a higher
risk for the development of AD.
AD pathology has become increasingly linked with
inflammation, specifically among Non-Hispanic whites
[4,10,11]. IL-5, -6, and -7 were found to be some of the
top serum-based proteins among individuals with AD [4].
Although inflammatory blood-based biomarkers have been
established as predictors of AD presence, outside our labora-
tory, few studies to date have sought to examine how much
variance is accounted for by the biomarkers themselves in
relation to measures of cognition [7]. Given that these bio-
markers are associated with AD, it is hypothesized that the
markers will account for a significant amount of variance
in memory scores. This project sought to examine molecular
markers of neuropsychological functioning among elders
with and without AD and sought to determine the predictive
ability of combined molecular markers and select neuropsy-
chological tests in detecting disease presence.2. Methods
2.1. Participants
Data were analyzed from 300 participants (n 5 150, AD
and n 5 150, normal cognition) enrolled in the Texas Alz-
heimer’s Research and Care Consortium (TARCC). The
TARCC protocol has been well documented elsewhere
[12,13]. Briefly, the methodology for the TARCC study
includes having each participant undergo an annual
standardized assessment at one of the six participating
sites, which includes a medical evaluation, neuro-
psychological evaluation, a clinical interview, and a blood
draw. The diagnosis of AD is based on National Institute
of Neurological and Communicative Disorders and Stroke
and the Alzheimer’s Disease and Related Disorders
Association criteria [14] and healthy controls performed
within normal limits on neuropsychological testing. All par-
ticipants also had a Clinical Dementia Rating (CDR) as-
signed. Institutional Review Board approval was obtained
at each site and written and informed consent was obtained.2.2. Human serum sample collection
Nonfasting blood samples were collected in 10 ml of tiger-
top tubes.Theobtained serumsampleswere allowed to clot in a
vertical position for approximately 30minutes at room temper-
ature. The samples are then centrifuged for 10 minutes at the
speed of 1300 !g within 1 hour of collection. Then 1.0 ml
of aliquots of serum are transferred into cryovial tubes with
Freezerworks barcode labels firmly affixed to each aliquot.
Samples are then placed in 280C freezer within 2 hours of
collection for storage until use in an assay. Serumwas assayed
in duplicate via a multiplex biomarker assay platform using
electrochemiluminescence (ECL) on the SECTOR Imager
2400A from Meso Scale Discovery (MSD; http://www.
mesoscale.com). TheMSDplatformhas been used extensively
to assay biomarkers of AD [15,16]. ECL measures are
considered to be more conventional than those of enzyme-
linked immunosorbent assay, which are the current standard
for most assays because of their increased sensitivity [15].
2.3. Neuropsychological testing
The core neuropsychology battery for the TARCC includes
commonly used instruments for detection of AD in both clin-
ical and in research settings. Thebattery includes the following
tests: Trail-Making Test [17], Boston Naming Test (30- and
60-items versions) [18], verbal fluency (Controlled Oral
Word Association Task [COWAT], Animals) [18], Clock-
Drawing Test (4-points) [18], American National Adult
Reading Test [18], digit span (Wechsler Adult Intelligence
Scale-Revised, Wechsler Adult Intelligence Scale Third Edi-
tion, Wechsler Memory Scale-Revised [WMS-R]) [19],
WMS Logical Memory and Visual Reproduction (WMS-R
and WMS-III) [19], the Geriatric Depression Scale (GDS-
30) [20], theMini-Mental State Examination [21], and ratings
on theCDR[22]. Scoreswere equated acrossversions byusing
scale scores as outcome variables in analyses.
2.4. Statistical analyses
Linear regression models were created to examine the
link between the top five molecular markers from our AD
blood profile [4] (IL-5, IL-6, IL-7, TNF-a, CRP) and neuro-
psychological test scores. Next, logistical regressions were
used to predict AD presence using the serum biomarkers
in combination with the select neuropsychological measures
that were least related to the biomarker profile.3. Results
Demographic characteristics of the TARCC samples are
presented in Table 1. AD cases were found to be older
(P , .001), have fewer years of education (P 5 .003) and
be predominantly female (P, .001). Significant differences
were also observed across the molecular markers used.
Those with AD, were found to have higher levels of IL-7
(P , .001), TNF-a (P , .001), and IL-6 (P , .001) as
Table 1
Demographic characteristics
Alzheimer’s disease mean (SD) Normal control mean (SD)
Mean (SD) Range Mean (SD) Range
Gender, male 30% 32%
Age 76.1 (8.6) 54–105 71.2 (9.2) 50–94
Education 14.7 (3.0) 0–23 15.5 (2.6) 0–23
Race/ethnicity
Hispanic Mexican American 3% 7%
Non-Hispanic white 96% 90%
CDR-SB 7.8 (4.1) 0–18 0.0 (0.1) 0–3
MMSE 19.1 (6.3) 0–30 29.1 (1.4) 18–30
COWAT scaled score 7.2 (3.4) 2–18 10.9 (3.1) 2–18
CRP (mg/L) 3.0 (4.4) 0–25.0 4.1 (4.2) 0.1–25.0
IL-5 (mg/L) 3.1 (19.6) 0.4–32.0 3.8 (18.7) 0.4–26.0
IL-6 (mg/L) 5.0 (5.5) 0.7–43.0 2.1 (2.2) 0.2–13.0
IL-7 (mg/L) 10.4 (4.4) 6.5–376.0 5.0 (2.5) 6.5–263.0
TNF-a (mg/L) 3.4 (3.6) 1–64 1.3 (0.8) 1–93
Abbreviations: SD, standard deviation; CDR-SB, Clinical Dementia Rating; MMSE, Mini-Mental State Health Examination; CRP, C-reactive protein; IL,
interleukin; TNF-a, tumor necrosis factor.
Table 2







Demographics 1 COWAT 0.76 0.77 0.77
Demographics 1 IL-5, IL-6,
IL-7, CRP, TNF-a
0.87 0.88 0.87
Demographics 1 IL-5, IL-6,
IL-7, CRP, TNF-a 1 COWAT
0.90 0.92 0.91
Abbreviations: COWAT, Controlled Oral Word Association Task;
IL, interleukin; CRP, C-reactive protein; TNF-a, tumor necrosis factor.
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ences were also identified wherein lower levels were found
among AD cases in CRP (P 5 .001) levels and there was
also a trend toward significance related to lower IL-5
(P 5 .05) levels.
The combined molecular markers were significantly
related to cognitive test scores and accounted for a significant
amount of variance: COWAT (B[SE] 5 20.62[0.12],
P , .001, 5%), Logical Memory I (B[SE] 5 215.59
[502.18], P 5 .97, 19%), Logical Memory II (B
[SE]5 29.18[554.95], P5 .98, 20%), Visual Reproduction
I (B[SE] 5 21.37[0.34], P , .001, 19%), Visual Reproduc-
tion II (B[SE] 5 247.16[599.87], P 5 .93, 22%), trail mak-
ing test A (B[SE] 5 20.49[0.10], P , .001, 8%), trail
making test B (B[SE] 5 20.57[0.10], P , .001, 13%), and
Boston naming test 60-item (B[SE] 5 20.54[0.10],
P , .001, 14%). The COWAT was found to have the least
amount of variance overlap with the molecular markers and
was selected for combination with the markers for predicting
AD presence. This was done to maximize the strengths of the
approach by minimizing overlap. The COWAT requires par-
ticipants to generate words that begin with a specific letter of
the alphabet within a predetermined time frame [18]. The
COWAT is designed to test for verbal fluency, specifically,
phonemic fluency. In prior work, the COWAT has been
shown to distinguish mildly impaired AD cases from normal
controls due to its requirement of concurrent manipulation of
information (set formation and set shifting) [23].
When examining the predictive ability of the biomarker-
cognitive profile in detecting AD (Table 2), the combination
of demographic variables 1 five molecular markers alone
were relatively accurate in detecting disease presence (Area
Under the Curve [AUC] 5 0.87). Lower accuracy was de-
tectedwhen combining only demographic factors1 one neu-
ropsychological test (COWAT) (AUC 5 0.77).
Comparatively, the combination of demographics1 one neu-ropsychological test (COWAT) 1 five molecular markers
were found to be highly accurate in detecting AD presence
(sensitivity and specificity of 90% and 92%, respectively)
with an overall accuracy of 91%.4. Conclusions
A combination of blood-based biomarkers 1 cognitive
measure1 demographics has yielded excellent diagnostic ac-
curacy in detecting the presence of AD even in early stages
[8]. The current project sought to further refine prior research
by examining the strength of the relationship of the top five
molecular markers from our recently publishedAD algorithm
[4] with neuropsychological test scores. The molecular
markers accounted for a significant amount of variance in neu-
ropsychological test scores, specificallywithmeasures related
tomemory. This finding is not surprising given that the blood-
based biomarker algorithm is highly accurate in detecting AD
where memory deficits are the core cognitive feature. Among
the neuropsychological measures, the COWAT a measure of
phonemic fluency had the least amount of shared variance
with the molecular markers. Combining five molecular
markers with this single neuropsychological test yielded an
excellent overall accuracy of 91%.
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supported their link with the domains of language, executive
functioning, and memory [3]. There is extensive literature to
support the association between verbal fluency deficits and
AD with several studies indicating that changes in verbal
fluency can begin up to five years before diagnosis [24,25].
Additional studies have shown a pronounced decrease in
the ability to generate words among those with AD
pathology [26–30]. Impaired phonemic fluency has been
linked to greater executive dysfunction and may provide a
better assessment of the frontal regions of the brain when
compared with semantic network tasks [31]. Moreover,
some studies suggest that phonemic fluency is only mildly
impaired among AD cases compared with other measures
of verbal fluency [29,32–34]. Therefore, subtle changes in
phonemic fluency may represent underlying pathological
changes, which are sensitive to changes in disease state.
With regards to the molecular marker change in CRP
levels observed between diagnostic groups, our findings
are consistent with prior work from our group and others
who have previously found CRP levels to be decreased
among non-Hispanic white AD cases as compared with
cognitively normal controls [35–37]. However, we have
also found increased CRP levels to be related to poorer
outcomes among Hispanics, findings which have been
replicated by others [37,38]. There is consistent evidence
to suggest that inflammatory processes, marked by
fluctuations in markers such as CRP or IL-5, are linked
with risk for late life AD [2–4,35–38]. Work related to
inflammatory processes among our group has led to the
proposed existence of a proinflammatory endophenotype,
which can explain noted molecular marker changes with
increased disease severity [2–4]. Additional work will
seek to address the proposed endophenotype along
with changes this may pose to the molecular marker 1
cognitive measure profile for disease presence particularly
across ethnicities.
There are several limitations with this study that impact
the generalizability of the findings. One limitation is the de-
mographics of the sample, which is comprised predomi-
nately of white, well-educated, females. Additionally, the
TARCC battery is heavily weighted toward measures of
memory and further research using other measures of exec-
utive functioning may enhance the utility of the approach. It
is also possible that stage of disease is differentially
impacted by the selected molecular markers, which impli-
cates that a different measure of cognitive functioning could
be more reliable in detecting the presence of AD at earlier
stages. Follow-up work is being conducted to examine this
potential to establish relative changes in molecular
markers 1 cognitive measures in detecting disease pres-
ence/severity from subjective memory complaints and
mild cognitive impairment stages to AD.
Use of a point-of-care device, which incorporates molec-
ular markers with cognitive measures, has significant utility
in clinical settings particularly within primary care. Asphysicians have a limited amount of time with patients, a
time-and cost-effective measure to identify those who would
benefit from follow-up assessments at a specialty care clinic
has the potential to increase early diagnostics and provide
necessary care early on, when it is most effective. Addition-
ally, a point-of-care device has the opportunity to serve as a
means of screening into clinical trials and aid in the differen-
tial diagnoses as several neurodegenerative diseases present
with similar symptoms at onset. Moreover, minority popula-
tions often present earlier with cognitive impairment and
frequently go undiagnosed until later stages in the disease.
A point-of-care device could help serve this population
and increase access to care and appropriate treatment refer-
rals.
Combining a measure of verbal fluency that reflects exec-
utive functioning with biomarkers that are more strongly
related to memory processes produces a highly accurate
tool to detect Alzheimer’s disease. This work provides the
foundation for the generation of a point-of-care device that
can be used to screen for AD with screen positives referred
for a comprehensive dementia examinations, including am-
yloid beta positron emission tomography scans, cerebrospi-
nal fluid, and/or clinical evaluations. Further research
focusing on the use of this combination in individuals with
subjective cognitive complaints or mild cognitive impair-
ment, may allow increased ability to predict cognitive
decline or conversion to Alzheimer’s. Our work is the first
to combine molecular markers with measures of cognition
in an effort to identify AD. More research is needed to
examine the broader implications of combining molecular
markers with cognitive measures for purposes of enhancing
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Polk.RESEARCH IN CONTEXT
1. Systematic review: A literature review was conduct-
ed to evaluate the current state of work examining the
use of blood-based biomarkers in the detection of
Alzheimer’s disease (AD). Prior research looking at
the utility of implementing molecular markers with
cognitive measures for purposes of screening for AD
presence was also reviewed.
2. Interpretation: Molecular markers were found to
differentially relate to specific cognitive measures,
with the measure of verbal fluency showing the least
amount of variance. When select molecular markers
were combined with one measure of fluency and de-
mographics it was highly accurate in the detection
of AD.
3. Future directions: This work seeks to establish a
point-of-care device that can be used for diagnostic
and prognostic purposes for AD. Further work
should focus on this combination of molecular
markers and cognitive measures among individuals
with subjective cognitive complaints or mild cogni-
tive impairment.References
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